Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study.
Saved in:
| Title: | Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study. |
|---|---|
| Authors: | Canino, Fabio1 (AUTHOR) fabio.canino@unimore.it, Barbolini, Monica2 (AUTHOR), De Giorgi, Ugo3 (AUTHOR), Fontana, Tommaso4 (AUTHOR), Gaspari, Valeria5 (AUTHOR), Gianni, Caterina3 (AUTHOR), Gianni, Lorenzo5 (AUTHOR), Maestri, Antonio6 (AUTHOR), Minichillo, Santino6 (AUTHOR), Moscetti, Luca2 (AUTHOR), Mura, Antonella6 (AUTHOR), Nicoletti, Stefania Vittoria Luisa5 (AUTHOR), Omarini, Claudia2 (AUTHOR), Pagani, Rachele4 (AUTHOR), Sarti, Samanta3 (AUTHOR), Toss, Angela1,2 (AUTHOR), Zamagni, Claudio4 (AUTHOR), Cuoghi Costantini, Riccardo7 (AUTHOR), Caggia, Federica1 (AUTHOR), Antonelli, Giuseppina1 (AUTHOR) |
| Source: | BMC Cancer. 6/15/2024, Vol. 24 Issue 1, p1-18. 18p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
